Progress of epidermal growth factor receptor-tyrosine kinase inhibitor targeted therapy in Chinese patients with non-small cell lung cancer
10.3760/cma.j.cn115355-20220326-00180
- VernacularTitle:我国非小细胞肺癌患者表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展
- Author:
Shichao ZHANG
1
;
Zifang ZHU
;
Xinping XU
;
Xiaolei LI
Author Information
1. 南昌大学医学院，南昌 330000
- Keywords:
Carcinoma, non-small-cell lung;
Drug resistance, neoplasm;
Receptor, epidermal growth factor;
Enzyme inhibitors;
Mutation;
Targeted therapy
- From:
Cancer Research and Clinic
2022;34(9):702-705
- CountryChina
- Language:Chinese
-
Abstract:
Cell epidermal growth factor receptor (EGFR) mutation is one of the causes of non-small cell lung cancer (NSCLC). The emergence of targeted drugs for EGFR gene mutation provides a new direction for NSCLC treatment. The common EGFR-targeted drugs like the first-generation gefitinib and erlotinib, the second-generation afatinib and the third-generation osimertinib have shown their good efficacies in a number of large international clinical trials. EGFR gene mutation in Chinese NSCLC patients is different from that in European and American NSCLC patients. This paper briefly reviews the characteristics of EGFR gene mutation and the current status and progress of EGFR-targeted drugs in Chinese NSCLC patients to investigate the mutation characteristics of EGFR in Chinese NSCLC patients and the response as well as prognosis of Chinese patients to EGFR-TKI therapy.
